Dennis McBride - NRX Pharmaceuticals Chief Scientist

NRXP Stock  USD 2.27  0.02  0.87%   

Insider

Dennis McBride is Chief Scientist of NRX Pharmaceuticals
Phone484 254 6134
Webhttps://www.nrxpharma.com

NRX Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (1.4566) % which means that it has lost $1.4566 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.8261) %, meaning that it created substantial loss on money invested by shareholders. NRX Pharmaceuticals' management efficiency ratios could be used to measure how well NRX Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
NRX Pharmaceuticals currently holds 9.16 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. NRX Pharmaceuticals has a current ratio of 4.49, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about NRX Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

James CollinsSenti Biosciences
58
Inbal BenjaminiElranBiomx Inc
N/A
Tomasz GeorgeVirax Biolabs Group
40
MD FACCLongeveron LLC
62
Philip LeeSenti Biosciences
42
Jonathan MBABiomx Inc
48
Vanessa CarleLexaria Bioscience Corp
N/A
Assaf OronBiomx Inc
50
CPA CMALexaria Bioscience Corp
63
Christopher BunkaLexaria Bioscience Corp
62
Angela NelmsRenovoRx
47
Eran MDBiomx Inc
N/A
Jason DavisVirax Biolabs Group
53
Ramtin MDRenovoRx
59
James FosterVirax Biolabs Group
40
Deborah KnobelmanSenti Biosciences
50
Susan KahlertSenti Biosciences
N/A
James AhlersRenovoRx
60
Jeffrey PharmDNutriband
55
Michael MyersQuoin Pharmaceuticals Ltd
63
Ronald CPARenovoRx
N/A
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded in 2015 and is based in Wilmington, Delaware. Nrx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. NRX Pharmaceuticals (NRXP) is traded on NASDAQ Exchange in USA. It is located in 1201 Orange Street, Wilmington, DE, United States, 19801 and employs 14 people. NRX Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

NRX Pharmaceuticals Leadership Team

Elected by the shareholders, the NRX Pharmaceuticals' board of directors comprises two types of representatives: NRX Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NRX. The board's role is to monitor NRX Pharmaceuticals' management team and ensure that shareholders' interests are well served. NRX Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NRX Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Suzanne Messere, Investor Relations
Michael Abrams, Chief Officer
Robert MIM, Chief Operations
Michael Kunz, Gen Sec
Stephen Esq, CEO Secretary
Richard Narido, Principal CFO
Molly Cogan, Sr Affairs
Seth Voorhees, CFO Treasurer
Dennis McBride, Chief Scientist
Matthew Duffy, Chief Therapeutics
Prof Javitt, CoFounder Board
Riccardo Panicucci, Chief Officer
MPH MD, Chief CoFounder
Philip Lavin, Chief Methodologist

NRX Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NRX Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Additional Tools for NRX Stock Analysis

When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.